| Literature DB >> 28900413 |
Ming-Kuei Lu1,2,3, Jui-Cheng Chen1,2,3, Chun-Ming Chen3,4, Jeng-Ren Duann5,6, Ulf Ziemann7, Chon-Haw Tsai1,2,3.
Abstract
BACKGROUND: Functional perturbation of the cerebellum (CB)-motor cortex (M1) interactions may underlie pathophysiology of movement disorders, such as Parkinson's disease (PD) and spinocerebellar ataxia type 3 (SCA3). Recently, M1 motor excitability can be bidirectionally modulated in young subjects by corticocortical paired associative stimulation (PAS) on CB and contralateral M1 with transcranial magnetic stimulation (TMS), probably through the cerebello-dentato-thalamo-cortical (CDTC) circuit. In this study, we investigated the CB to M1-associative plasticity in healthy elderly PD and SCA3.Entities:
Keywords: Parkinson’s disease; cerebellar inhibition; motor cortex; paired associative stimulation; spinocerebellar ataxia type 3
Year: 2017 PMID: 28900413 PMCID: PMC5581840 DOI: 10.3389/fneur.2017.00445
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Demographic and clinical characteristics of the Parkinson’s disease (PD) and spinocerebellar ataxia type 3 (SCA3) patients.
| PD group (No.) | Age (years) | Sex | Disease duration (years) | Motor/total UPDRS (more affected side) | Hoehn and Yahr stage | Medication (daily dose in mg) (LED) |
|---|---|---|---|---|---|---|
| 1 | 66 | F | 3 | 38/55 (L) | 2.5 | Levodopa 300 (300) |
| 2 | 70 | M | 8 | 48/64 (L) | 3 | Levodopa 350, trihexyphenidyl 3, amantadine 300, rotigotine 4 (770) |
| 3 | 67 | F | 7 | 18/22 (L) | 2 | Levodopa 300, biperiden 4, ropinirole PR 4 (380) |
| 4 | 57 | M | 6 | 27/33 (L) | 2 | Levodopa 300, pramipexole 0.75, amantadine 300 (675) |
| 5 | 79 | F | 5 | 32/45 (L) | 2.5 | Levodopa 100, amantadine 100, propranolol 20 (200) |
| 6 | 82 | M | 5 | 27/41 (R) | 2.5 | Levodopa 300, entacapone 600, amantadine 100, propranolol 30 (499) |
| 7 | 75 | M | 1 | 16/31 (R) | 2 | Levodopa 100 (100) |
| 8 | 80 | M | 3 | 24/30 (L) | 2 | Levodopa 200 (200) |
| 9 | 62 | M | 2 | 28/40 (R) | 2 | Levodopa 300, biperiden 3, ropinirole 0.75 (315) |
| 10 | 53 | M | 3 | 15/26 (R) | 2 | Levodopa 200 (200) |
| 1 | 47 | M | 20 | 13 | 73 | Levodopa 100, amantadine 100, baclofen 20, piracetam 2,400 (200) |
| 2 | 62 | F | 3 | 11 | 62 | Amantadine 150, biperiden 3 (150) |
| 3 | 43 | M | 16 | 21 | 82 | Amantadine 300, trihexyphenidyl 4, tizanidine 9, flunarizine HCl 15 (300) |
| 4 | 75 | F | 13 | 24 | 66 | Alprazolam 0.25 (0) |
| 5 | 30 | F | 4 | 12 | 76 | Tizanidine 3, amantadine 300 (300) |
| 6 | 59 | F | 10 | 22 | 71 | None (0) |
| 7 | 62 | M | 2 | 12 | 66 | Piracetam 2,400 (0) |
| 8 | 30 | F | 3 | 12 | 76 | Amantadine 150 (150) |
| 9 | 39 | F | 3 | 14 | 74 | Levodopa 100, amantadine 100 (200) |
.
F, female; L, left; LED, .
Baseline parameters of transcranial magnetic stimulation (TMS) in the three groups.
| RMT (%MSO) | AMT (%MSO) | MEP1mV | Inion AMT (%MSO) | Conditional TMS intensity for SICI (%MSO) | Baseline SICI | Conditional TMS intensity for ICF (%MSO) | Baseline ICF | Conditional TMS intensity for CBI (%MSO) | Baseline CBI | |
|---|---|---|---|---|---|---|---|---|---|---|
| HC | 51.6 ± 7.9 | 47.3 ± 8.1 | 67.0 ± 12.4 | 44.1 ± 4.5 | 40.0 ± 5.5 | 45.9 ± 22.9 | 40.0 ± 5.5 | 148.7 ± 32.7 | 41.9 ± 4.3 | 84.7 ± 15.1 |
| PD | 48.6 ± 10.4 | 44.6 ± 9.3 | 65.1 ± 15.6 | 42.1 ± 4.5 | 40.2 ± 8.7 | 62.4 ± 30.7 | 39.7 ± 9.5 | 147.9 ± 41.2 | 40.0 ± 4.3 | 91.9 ± 21.6 |
| SCA3 | 50.9 ± 7.6 | 47.1 ± 7.2 | 61.1 ± 13.7 | 44.1 ± 5.1 | 42.3 ± 7.5 | 79.1 ± 41.1 | 42.3 ± 7.7 | 146.3 ± 62.7 | 41.9 ± 4.9 | 101.9 ± 17.2 |
Data are presented as mean ± SD.
.
.
.
AMT, active motor threshold; CBI, cerebellar inhibition; HC, health control; ICF, intracortical facilitation; MSO, maximum stimulator output; PD, Parkinson’s disease; RMT, resting motor threshold; SCA3, spinocerebellar ataxia type 3; SICI, short-interval intracortical inhibition.
Figure 1(A) Motor-evoked potential (MEP) amplitudes (mean ± SEM in mV) recorded from the right first dorsal interosseus muscle in the healthy control (HC), Parkinson’s disease (PD), and spinocerebellar ataxia 3 (SCA3) groups. Comparisons between pre- (B0), immediate (P1), 30 min (P2), and 60 min (P3) post-CB → M1 PAS2ms vs. CB → M1 PAS6ms were shown. A significant MEP facilitation at P1 after CB → M1 PAS2ms and MEP suppression at P1 and P2 after CB → M1 PAS6ms were noted for the HC group (*P < 0.05 by non-parametric Mann–Whitney U test with Bonferroni’s correction). (B) The averaged MEP waveforms for the 10 subjects in the HC group. (C) Individual MEP data of the HC group (n = 10).
Figure 2Mean short-interval intracortical inhibition (SICI) [given as percentage of the conditioned motor-evoked potential (MEP)/unconditioned MEP] in the three groups. Note that the spinocerebellar ataxia type 3 (SCA3) group showed a significant reduction of SICI compared to the healthy control (HC) group (*P < 0.05 by non-parametric Mann–Whitney U test).
Figure 3Mean cerebellar inhibition (CBI) [given as percentage of the conditioned motor-evoked potential (MEP)/unconditioned MEP] in the three groups. In the healthy control (HC) group, there was a significant reduction of CBI at P1 and P3 compared to B0 (*P < 0.05 by non-parametric Mann–Whitney U test). The spinocerebellar ataxia type 3 (SCA3) group showed a significant reduction of the mean CBI compared with the HC group at B0 (#P < 0.05 by non-parametric Mann–Whitney U test). Compared to the PD group, the HC group showed a significant reduction of the mean CBI at P3 (#P < 0.05 by non-parametric Mann–Whitney U test).